temozolomida-100
flagship biotech international.. - temozolomida - cápsula - 100 mg
temozolomida-250
flagship biotech international.. - temozolomida - cápsula - 250 mg
mavenclad® 10 mg
nerpharma s.r.l. - cladribina - comprimido - 10 mg
lebrina 0,5 mg capsulas
laboratorios nolver, c.a. - fingolimod - capsulas - 0,5 mg
mitoxantrona 20mg/10ml concentrado para solucion para perfusion
global med farma s.a.c. - droguerÍa - concentrado para solucion para perfusion - por mililitro - - mitoxantrona
zeposia
bristol-myers squibb pharma eeig - ozanimod clorhidrato de - multiple sclerosis, relapsing-remitting; colitis, ulcerative - inmunosupresores - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
fampridine accord
accord healthcare s.l.u. - fampridina - esclerosis múltiple - otras drogas del sistema nervioso - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).
kesimpta solución inyectable 20 mg/0,4 ml (ofatumumab)
novartis chile s.a. - ofatumumab - sin formulas
spevigo
boehringer ingelheim international gmbh - spesolimab - psoriasis - inmunosupresores - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.
ciclofosfamida dr. reddys 500 mg/ml concentrado para solucion inyectable y para perfusion
reddy pharma iberia s.a. - ciclofosfamida monohidrato - concentrado para soluciÓn inyectable y para perfusiÓn - 2.000 mg inyectable 4 ml - ciclofosfamida monohidrato 500 mg - ciclofosfamida